CORT - コ―セプト・セラピュ―ティクス (Corcept Therapeutics Incorporated)

CORTのニュース

   Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates  2020/05/04 23:05:06 Zacks Investment Research
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Cushing's Syndrome Pipeline Insight, 2020 Featuring Novartis Pharmaceuticals, Cortendo AB, Corcept Therapeutics and HRA Pharma - ResearchAndMarkets.com  2020/05/01 16:31:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Cushing's Syndrome Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Cushing's Syndrome market. A detailed picture of the Cushing's Syndrome pipeline landscape is provided, which includes the disease overview and Cushing's Syndrome treatment guidelines. The assessment part of the report embraces in-depth Cushi
   Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice  2020/04/27 16:00:07 Zacks Investment Research
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
   Corcept Therapeutics' Shares March Higher, Can It Continue?  2020/04/13 12:31:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.
   Why You Shouldn't Bet Against Corcept Therapeutics (CORT) Stock  2020/04/02 13:51:00 Zacks Investment Research
Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Corcept (CORT) Down 24.9% Since Last Earnings Report: Can It Rebound?  2020/03/21 15:30:56 Zacks Investment Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)  2020/02/24 17:41:00 Business Wire
SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)---- $CORT #ClassAction--Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the Securities Exchange Act of 1934. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept's drug Korylm is a cortisol receptor blocker used to control
   Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y  2020/02/21 19:25:00 Zacks Investment Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
   Why Corcept (CORT) Could Beat Earnings Estimates Again  2020/02/19 17:10:06 Zacks Investment Research
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
   Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)  2020/02/24 17:41:00 Business Wire
SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)---- $CORT #ClassAction--Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the Securities Exchange Act of 1934. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept's drug Korylm is a cortisol receptor blocker used to control
   Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y  2020/02/21 19:25:00 Zacks Investment Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
   Why Corcept (CORT) Could Beat Earnings Estimates Again  2020/02/19 17:10:06 Zacks Investment Research
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
   What's in Store for Corcept (CORT) This Earnings Season?  2020/02/18 10:04:00 Zacks Investment Research
During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.
   Corcept Therapeutics (CORT) to Report Q4 Results: What Awaits?  2020/02/17 17:30:46 Zacks Investment Research
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

calendar